Viking to push obesity drug to Phase 3 in bid to reach market faster

Nicole DeFeudis

Editor

Viking Therapeutics is stepping on the gas with its experimental GLP-1/GIP receptor agonist for obesity, forgoing a Phase 2b study and jumping right into Phase …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Viking to push obesity drug to Phase 3 in bid to reach market faster

Nicole DeFeudis

Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

Viking to push obe­si­ty drug to Phase 3 in bid to reach mar­ket faster

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Viking to push obesity drug to Phase 3 in bid to reach market faster